GOLMePsA RCT early naive PsA Golimumab or PBO in addition to MTX+IM GCs No difference wk52 ACR20 GOL 76% PBO 55% MDA GOL
Tweet Content
GOLMePsA RCT early naive PsA
Golimumab or PBO in addition to MTX+IM GCs
No difference wk52
ACR20 GOL 76% PBO 55%
MDA GOL 55% PBO 41%
PBO arm received higher GC dose
No new safety signal
@RheumNow AbstOP0148 #EULAR2024 https://t.co/bj7YNXhssm
Show on Archive Page
On
Display in Search Results
On
PDQ
Off